Company intelligence / Profile preview
Genosco
Boston, Massachusetts, United Statesgenosco.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Commercial
01
Overview
Genosco’s most advanced asset, lazertinib, is an EGFR inhibitor for NSCLC. It has received regulatory approval in Korea for first and second-line therapy, with FDA approval in the US as of August 2024 and EU EC approval as of December 2024. The company also has multiple programs at preclinical to clinical stages targeting various autoimmune diseases, fibrosis, cancer/immuno-oncology indications, and CNS disorders. Their G-SMART™ platform underpins their pipeline by enabling rapid discovery of selective kinase inhibitors.
- Therapeutic areas
- GastroenterologyPulmonologyImmunologyDermatologyHematologyOncologyNeurology
- Modalities
- Small moleculesKinase inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Janssen
Beyond the preview
Go deeper on Genosco.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genosco.